HIGHLIGHTS
- who: L. Weiss from the Department of Medicine III, University Hospital, LMU, Germany have published the paper: Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective, in the Journal: (JOURNAL)
- what: The authors aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients. To investigate the benefit with regard to the overall survival and rates of implementation of the MTB recommendation, the authors report clinical outcomes of a cohort of 61 patients with CUP syndrome. 20 patients were excluded from the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.